
April 30 (Reuters) - Surmodics Inc SRDX.O:
SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE
SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS
SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES
SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY